本文已被：浏览 1232次 下载 2256次
Received:December 10, 2022 Published Online:June 20, 2023
Received:December 10, 2022 Published Online:June 20, 2023
中文摘要: 小细胞肺癌（SCLC）是一种高侵袭性的恶性肿瘤,病情进展快,短期内易复发,预后极差。美国国家癌症研究所将SCLC认定为一种难治性疾病。近年来,免疫治疗在广泛期SCLC（ES-SCLC）的治疗上取得了突破性进展,基于IMpower 133和CASPIAN研究结果,阿替利珠单抗（atezolizumab）联合化疗和度伐利尤单抗（durvalumab）联合化疗均获批了ES-SCLC一线治疗适应证,开启了ES-SCLC免疫治疗新时代。本文将对细胞毒性T淋巴细胞抗原-4（CTLA-4）抑制剂和程序性死亡蛋白-1（PD-1）/程序性死亡配体-1（PD-L1）抑制剂治疗SCLC的临床研究进展及生物标志物进行综述。
Abstract:Small cell lung cancer (SCLC) is a highly aggressive malignancy with rapid disease progression, easy recurrence in the short term and extremely poor prognosis. SCLC is recognized as a refractory disease by the National Cancer Institute. In recent years, immunotherapy has made breakthrough progress in the treatment of extensive stage SCLC (ES-SCLC) , based on IMpower133 and CASPIAN findings, atezolizumab combined with chemotherapy and durvalumab combined with chemotherapy both approved first-line treatment indications for ES-SCLC, opening a new era of immunotherapy for ES-SCLC. In this review, the clinical research progress and biomarkers of cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors and programmed cell death-1 (PD-1) /programmed cell death ligand-1 (PD-L1) inhibitors for SCLC will be reviewed.
keywords: Extensive stage small cell lung cancer Small cell lung cancer Lung cancer Immune checkpoint inhibitors Cytotoxic T lymphocyte antigen-4 Programmed death Programmed death-ligand Atezolizumab Durvalumab
文章编号： 中图分类号：R734 文献标志码：A
基金项目:新疆维吾尔自治区自然科学基金面上项目 (2022D01C294)
| Author Name | Affiliation |
| ZHENG Yang, Patiguli Aerxiding | Pulmonary Medicine Ward 1, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang 830000, China |
| Author Name | Affiliation |
| ZHENG Yang, Patiguli Aerxiding | Pulmonary Medicine Ward 1, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang 830000, China |
引用文本：